Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Methanococcus vannielii S-adenosylmethionine synthase (mat) CSB-YP413495MNS
CSB-EP413495MNS
CSB-BP413495MNS
CSB-MP413495MNS
CSB-EP413495MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii UPF0290 protein Mevan_1000 (Mevan_1000), partial CSB-YP413496MNS1
CSB-EP413496MNS1
CSB-BP413496MNS1
CSB-MP413496MNS1
CSB-EP413496MNS1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii GTP cyclohydrolase mptA (mptA) CSB-YP413497MNS
CSB-EP413497MNS
CSB-BP413497MNS
CSB-MP413497MNS
CSB-EP413497MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii DNA-binding protein Mevan_1162 (Mevan_1162) CSB-YP413498MNS
CSB-EP413498MNS
CSB-BP413498MNS
CSB-MP413498MNS
CSB-EP413498MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii 3-dehydroquinate synthase (Mevan_1215) CSB-YP413499MNS
CSB-EP413499MNS
CSB-BP413499MNS
CSB-MP413499MNS
CSB-EP413499MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii Phosphoribosyl-AMP cyclohydrolase (hisI) CSB-YP413500MNS
CSB-EP413500MNS
CSB-BP413500MNS
CSB-MP413500MNS
CSB-EP413500MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii 2,3-bisphosphoglycerate-dependent phosphoglycerate mutase (gpmA) CSB-YP413501MNS
CSB-EP413501MNS
CSB-BP413501MNS
CSB-MP413501MNS
CSB-EP413501MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii 30S ribosomal protein S24e (rps24e) CSB-YP413502MNS
CSB-EP413502MNS
CSB-BP413502MNS
CSB-MP413502MNS
CSB-EP413502MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii 7-cyano-7-deazaguanine tRNA-ribosyltransferase (tgtA), partial CSB-YP413503MNS
CSB-EP413503MNS
CSB-BP413503MNS
CSB-MP413503MNS
CSB-EP413503MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii 50S ribosomal protein L14e (rpl14e) CSB-YP413504MNS
CSB-EP413504MNS
CSB-BP413504MNS
CSB-MP413504MNS
CSB-EP413504MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii UPF0285 protein Mevan_1551 (Mevan_1551) CSB-YP413505MNS
CSB-EP413505MNS
CSB-BP413505MNS
CSB-MP413505MNS
CSB-EP413505MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii Proteasome subunit beta (psmB) CSB-YP413506MNS
CSB-EP413506MNS
CSB-BP413506MNS
CSB-MP413506MNS
CSB-EP413506MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus vannielii Hydroxylamine reductase (hcp), partial CSB-YP413507MNS
CSB-EP413507MNS
CSB-BP413507MNS
CSB-MP413507MNS
CSB-EP413507MNS-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus aeolicus Putative cobalt-precorrin-6A synthase [deacetylating] (cbiD) CSB-YP413508MNO
CSB-EP413508MNO
CSB-BP413508MNO
CSB-MP413508MNO
CSB-EP413508MNO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus aeolicus V-type ATP synthase alpha chain (atpA), partial CSB-YP413509MNO
CSB-EP413509MNO
CSB-BP413509MNO
CSB-MP413509MNO
CSB-EP413509MNO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus aeolicus Acetylglutamate kinase (argB) CSB-YP413510MNO
CSB-EP413510MNO
CSB-BP413510MNO
CSB-MP413510MNO
CSB-EP413510MNO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus aeolicus 6,7-dimethyl-8-ribityllumazine synthase (ribH) CSB-YP413511MNO
CSB-EP413511MNO
CSB-BP413511MNO
CSB-MP413511MNO
CSB-EP413511MNO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus aeolicus 50S ribosomal protein L1P (rpl1p) CSB-YP413512MNO
CSB-EP413512MNO
CSB-BP413512MNO
CSB-MP413512MNO
CSB-EP413512MNO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus aeolicus Nicotinamide-nucleotide adenylyltransferase (Maeo_0254) CSB-YP413513MNO
CSB-EP413513MNO
CSB-BP413513MNO
CSB-MP413513MNO
CSB-EP413513MNO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Methanococcus aeolicus UDP-N-acetyl-D-mannosamine dehydrogenase (wecC) CSB-YP413514MNO
CSB-EP413514MNO
CSB-BP413514MNO
CSB-MP413514MNO
CSB-EP413514MNO-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過(guò)多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過(guò)程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過(guò)多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過(guò)程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>